Document:

EXHIBIT 10.6

                                 LOAN AGREEMENT

      This Loan Agreement ("Agreement") is entered into as of November 5,
2002, by and between Gender Sciences, Inc., a New Jersey corporation (the
"Company"), and Francis A. Newman ("Lender").  The Company and Lender agree
as follows:

      1. Loan. Lender hereby lends to the Company the sum of $50,000 (the
"Loan").

      2. Note. The Loan shall be evidenced by a convertible promissory note (the
"Note") (a copy of which is attached as Exhibit "A") executed by the Company,
dated as of the date the Loan is made, providing for the payment of the
principal amount plus simple interest at the rate of eight percent (8%) per
annum, and payable on the third (3rd) anniversary of the date of this Agreement
("Maturity Date") at which time the entire unpaid balance of principal and all
accrued and unpaid interest shall be due and payable in a single installment.
Prior to the Maturity Date, the Note may be converted into the common or
preferred stock of the Company as provided hereinbelow. The Note shall also
provide that the Company may prepay the Note, in whole or in part, at any time
or from time to time upon fifteen (15) days' prior written notice to the Lender,
without penalty or additional fees; provided, however that the Lender shall be
first given the opportunity to convert the entire unpaid balance of principal
and accrued and unpaid interest thereon prior to any prepayment by the Company.

      3. Warrant. The Company shall, as further consideration, interest grant
Lender a Warrant to purchase 1,000,000 shares of Common Stock at a price per
share equal to Five Cents ($0.05) (the "Strike Price"); provided, however that
if, pursuant to the Qualifying Equity Financing (as defined below), the Company
sells (i) Common Stock at a price per share less than the Strike Price, then the
Company shall exchange the Warrant for a warrant to purchase the same number of
shares of Common Stock at a price per share equal to the price per share offered
in the Qualifying Equity Financing; or (ii) Preferred Stock at a price equal to
or less than the Strike Price, then the Company shall exchange the Warrant for
warrant to purchase the same number of shares of Preferred Stock at a price per
share equal to the price per share offered in the Qualifying Equity Financing.
The Warrant shall be substantially in the form of Exhibit "B," attached hereto
and incorporated herein.

      4. Conversion.

            4.1 Voluntary Conversion. If not sooner converted as described in
      Section 4.2 below, all or some of the outstanding principal balance of,
      and all or some of the accrued and unpaid interest on, the Note may be
      converted at any time prior to the Maturity Date, at the option of the
      Lender, into shares of Common Stock of the Company at a conversion price
      per share equal to Five Cents ($0.05).

            4.2 Automatic Conversion. At the closing of a Qualifying Equity
      Financing (as defined below) on or before the Maturity Date, the entire
      outstanding principal balance of, and all accrued and unpaid interest on,
      the Note shall be automatically converted into the number of shares of
      either (1) Preferred Stock or Common Stock, as the case may be, if the
      price per share in the Qualified Equity Financing is equal to or less than
      Five Cents ($0.05); or (2) Common Stock if the price per share is greater
      in the Qualified Equity Financing than Five Cents ($0.05), as is obtained

<PAGE>

      by dividing (a) the outstanding principal balance of, and all accrued and
      unpaid interest on, the Note as of the closing date of the Qualified
      Equity Financing by (b) the lower of (i) Five Cents ($0.05) or (ii) the
      price per share of Common Stock or Preferred Stock, as the case may be,
      issued in the Qualified Equity Financing. A "Qualified Equity Financing"
      shall mean an equity financing in which the Company sells shares of Common
      Stock or Preferred Stock and obtains net proceeds (including conversion of
      all convertible notes in connection with the bridge financing) in an
      amount not less than Two Million Dollars ($2,000,000).

            4.3 Exchange of Note. As promptly as practicable following the date
      of the Qualified Equity Financing, the Lender shall deliver the Note to
      the Company. The conversion of the Note shall be deemed to have been
      effected immediately upon the closing of the Qualified Equity Financing,
      and at such time the rights of the Lender to receive principal and
      interest shall cease, and the Lender shall be treated for all purposes as
      the record holder of the number of shares of Common Stock or Preferred
      Stock, as the case may be, into which this Note converts in accordance
      herewith. As promptly as practicable after the receipt of the Note from
      Lender, the Company shall cause to be issued and delivered to the Lender a
      certificate or certificates for the number of shares of Common Stock or
      Preferred Stock, as the case may be, issuable upon conversion of the Note.
      Such certificate or certificates shall bear such legends required, in the
      opinion of counsel for the Company, under applicable securities law.

            4.4 Fractional Shares. No fractional shares of shall be issued in
      connection with any conversion under the Note, but in lieu of such
      fractional shares, the Company shall round up the shares received upon
      conversion of the Note to the next whole share of stock.

            4.5 Converted Shares Subject to Lock Up. The shares of the Company's
      capital stock issued to Lender in conversion of the Note shall be subject
      to a lock-up agreement, wherein the holder of such shares agrees not to
      sell, assign or transfer the shares for a specific period of time
      following any underwritten public offering of the Company's securities.
      The holder of the converted shares agrees to sign a Lock-Up Agreement with
      terms no more restrictive than the Lock-Up Agreements entered into by the
      shareholders of the Company who are officers, directors or five percent
      (5%) shareholders of the Company.

            4.6 Restricted Shares Upon Conversion. The shares of the Company's
      stock issued to Lender in conversion of the Note shall be "restricted
      securities" as defined in Sections 7.6 and shall be subject to the
      limitations and legend conditions as set forth in Sections 7.7 through
      7.10 herein below.

            4.7 Reservation of Shares. The Company currently has enough
      authorized shares sufficient to effect the conversion of the Note and the
      exercise of the Warrant. Notwithstanding the foregoing, the Company's
      current authorized shares are not sufficient to effect the conversion of
      the Note and the exercise of the Warrant assuming full exercise and
      conversion of the Company's other outstanding options and convertible
      securities. Accordingly, the Company covenants and agrees to expeditiously
      take such corporate action as may be necessary to amend the Company's
      Articles of Incorporation to increase its authorized but unissued shares
      of capital stock to the number of shares as shall be sufficient for the
      conversion of all of its outstanding options and convertible securities.

                                       2

<PAGE>

      5. Conditions Precedent to Lender's Obligations. Lender's obligation to
disburse the Loan is subject to the condition that, on the date of disbursement
("Closing Date"), there shall have been delivered to Lender, in form and
substance satisfactory to Lender and its counsel:

            5.1 Note. The Note substantially in the form attached hereto as
      Exhibit "A," executed by a duly authorized officer of the Company.

            5.2 Warrant. The Warrant substantially in the form as attached
      hereto as Exhibit "B", executed by a duly authorized officer of the
      Company.

      6. Representations and Warranties of Company. The Company represents and
warrants that:

            6.1 Organization. The Company is a corporation duly organized and
      existing under the laws of the State of New Jersey with its principal
      place of business at 10 West Forest Avenue, Englewood, New Jersey 07631.
      It has the power to own its property and to carry on its business as it is
      now being conducted. It is duly qualified and authorized to do business
      and is in good standing in every state, country, or other jurisdiction in
      which the nature of its business and properties makes such qualification
      necessary.

            6.2 Authority. The Company has full power and authority (corporate
      and other) to borrow the sums provided for in this Agreement, to execute
      and deliver this Agreement, to issue the Warrant, the Note and any other
      instrument or agreement required under this Agreement, and to perform and
      observe the terms and provisions of this Agreement and of all such other
      instruments and agreements.

            6.3 Corporate Action. All corporate action by the Company, its
      directors or stockholders, necessary for the authorization, execution,
      delivery, and performance of this Agreement, issuance of the Warrant, and
      the Note and any other instrument or agreement required under this
      Agreement has been duly taken.

            6.4 Incumbency and Authority of Signators. The officers of the
      Company executing this Agreement, the Warrant, the Note and any other
      instrument or agreement required under this Agreement are duly and
      properly in office and fully authorized to execute them.

            6.5 Due and Valid Execution. This Agreement has been duly
      authorized, executed, and delivered by the Company, and is a legal, valid,
      and binding agreement of the Company, enforceable against the Company in
      accordance with its terms and the Warrant and the Note and any other
      instrument or agreement required under this Agreement has been so
      authorized and, when executed and delivered, will be similarly valid,
      binding and enforceable.

            6.6 Capitalization.

                  6.6.1 Conversion of Debt. Concurrently with the execution of
            this Agreement, the Two Hundred Forty Five Thousand Dollar
            ($245,000) loan from Unity Venture Capital Associates Ltd. ("UVCA")
            shall be converted into 4,900,000 shares of the Company's Common
            Stock, which are hereby deemed fully paid and non assessable in the
            form of a cancellation of a loan to the Company made by UVCA in the
            principal amount of Two Hundred Forty Five Thousand Dollars

                                       3

<PAGE>

            ($245,000) plus accrued interest thereon. As further consideration
            for the conversion of the loan, the Company shall issue UVCA a
            warrant to purchase 4,900,000 shares of the Company's Common Stock
            exercisable at a price per share equal to the Strike Price and
            subject to the same terms and conditions as the Warrant set forth
            above.

                  6.6.2 Capitalization Table. Attached hereto as Exhibit "E" is
            the Company's current capitalization table that sets forth the
            Company's current issued and outstanding stock and the total number
            of Common Stock post-financing (assuming a $0.05 exercise price) on
            an as-converted basis.

            6.7 Reserved Shares. The Company shall expeditiously take such
      corporate action as may be necessary to amend the Company's Articles of
      Incorporation to increase its authorized but unissued shares of capital
      stock to the number of shares as shall be sufficient for the conversion of
      the Note, Warrant and other outstanding options and convertible
      securities.

            6.8 No Violation. There is no charter, bylaw, or capital stock
      provision of the Company, and no provision of any indenture or agreement,
      written or oral, to which the Company is a party or under which the
      Company is obligated, nor is there any statute, rule, or regulation, or
      any judgment, decree, or order of any court or agency binding on the
      Company which would be contravened by the execution and delivery of this
      Agreement, the Warrant, the Note or any other instrument or agreement
      required under this Agreement, or by the performance of any provision,
      condition, covenant or other term of this Agreement, the Warrant, the Note
      or any such other instrument or agreement.

            6.9 Litigation Pending. There is no litigation, tax claim,
      proceeding or dispute pending, or, to the knowledge of the Company,
      threatened, against or affecting the Company or its property, the adverse
      determination of which might affect the Company's financial condition or
      operations or impair the Company's ability to perform its obligations
      under this Agreement or under the Warrant, the Note or any other
      instrument or agreement required by this Agreement.

      7. Representations and Warranties of Lender. This Agreement is made with
Lender in reliance upon Lender's representation and warranties to the Company,
which by Lender's execution of this Agreement Lender hereby confirms, that:

            7.1 Authorization. This Agreement constitutes Lender's valid and
      legally binding obligation, enforceable in accordance with its terms.

            7.2 Investment Intent. The Note and Warrant to be received by Lender
      will be acquired for investment for Lender's or his designee's, own
      account, not as a nominee or agent, and not with a view to the resale or
      distribution of any part thereof, and that Lender has no present intention
      of selling, granting any participation in, or otherwise distributing the
      same. By executing this Agreement, Lender further represents that Lender
      does not have any contract, undertaking, agreement or arrangement with any
      person to sell, transfer or grant participation to such person or to any
      third person, with respect to the Note or the Warrant or any capital stock
      underlying the Warrant.

            7.3 Enforceability. The Lender hereby represents and warrants that
      the execution and delivery by Lender of this Agreement, when duly executed
      by the other parties hereto, will result in legally binding obligations of

                                      4

<PAGE>

      Lender, enforceable against him, her or it in accordance with the
      respective terms and provisions hereof, except (a) as limited by
      applicable bankruptcy, insolvency, reorganization, moratorium or other
      laws of general application affecting enforcement of creditors' rights and
      (b) general principles of equity that restrict the availability of
      equitable remedies.

            7.4 Disclosure of Information. Lender has been provided with copies
      of the Company's Annual Report on Form 10-KSB for the year ended January
      31, 2002, the Company's Quarterly Reports on Form 10-QSB for the quarters
      ended April 30, 2002 and July 31, 2002 respectively and each Report on
      Form 8-K filed by the Company since January 1, 2002. In addition, Lender
      has been provided with a copy of the Company's proxy statement in
      connection with its most recent annual meeting of shareholders. Lender
      believes he/she/they have received all the information he/she/they
      consider necessary or appropriate for deciding whether to make the Loan,
      and acquire the Note and the Warrant. Lender further represents that
      he/she/they have had an opportunity to ask questions and receive answers
      from officers of the Company regarding the Company, its business and the
      terms and conditions of the Note and the Warrant. Lender recognizes that
      any investment in the Company must be considered to be highly speculative.

            7.5 Confidentiality. Lender hereby represents, warrants and
      covenants that he/she/they shall maintain in confidence, and shall not use
      or disclose without the prior written consent of the Company, any
      information identified as confidential that is furnished to him/her/them
      by the Company in connection with this Agreement. This obligation of
      confidentiality shall not apply, however, to any information (a) in the
      public domain through no unauthorized act or failure to act by Lender; or
      (b) lawfully disclosed to Lender by a third party who possessed such
      information without any obligation of confidentiality. Lender further
      covenants that he/she/they shall return to the Company all tangible
      materials containing such information upon request by the Company.

            7.6 Investment Experience. Lender is a lender and investor in notes
      and securities of companies in the development stage and acknowledges he/
      she/ they are able to fend for themselves, can bear the economic risk and
      complete loss of his/her/their investment and has such knowledge and
      experience in financial or business matters that he/she/they are capable
      of evaluating the merits and risks of the investment in the Note and the
      Warrant.

            7.7 Restricted Securities. Lender understands the Note, the shares
      resulting from the conversion of the Note, the Warrant and the shares
      underlying the Warrant he/she/they are acquiring are characterized as
      "restricted securities" under the federal securities laws in as much as
      they are being acquired from the Company in a transaction not involving a
      public offering and that under such laws and applicable regulations such
      securities may not be resold without registration under the Securities Act
      of 1933, as amended (the "Securities Act"), except in certain limited
      circumstances. In this connection Lender represents that he/she/they are
      familiar with Securities and Exchange Commission ("SEC") Rule 144, as
      presently in effect, and understand the resale limitations imposed thereby
      and by the Securities Act.

            7.8 Further Limitations on Disposition. Without in any way limiting
      the representations set forth above, Lender further agrees not to make any
      disposition of all or any portion of the Note, the shares resulting from

                                       5

<PAGE>

      the conversion of the Note, the Warrant or the shares underlying the
      Warrant unless and until:

                  7.8.1 There is then in effect a registration statement under
            the Securities Act covering such proposed disposition and such
            disposition is made in accordance with such registration statement;
            or

                  7.8.2 (i) Lender shall have notified the Company of the
            proposed disposition and shall have furnished the Company with a
            detailed statement of the circumstances surrounding the proposed
            disposition and (ii) if reasonably requested by the Company, Lender
            shall have the furnished the Company with an opinion of counsel,
            that such disposition will not require registration of such shares
            under the Securities Act.

            7.9 Legends.

                  7.9.1 It is understood the Note, the certificate representing
            the shares resulting from the conversion of the Note, the Warrant,
            or a certificate for the Company's stock evidencing the shares
            underlying the Warrant ("Certificate") may bear one or more of the
            following legends:

            "These securities have not been registered under the Securities Act
            of 1933. They may not be sold, offered for sale, pledged or
            hypothecated in the absence of a registration statement in effect
            with respect to the securities under such Act or an opinion of
            counsel satisfactory to the Company that such registration is not
            required or unless sold pursuant to Rule 144 of such Act."

            7.10 Accredited Investor. Lender is an "accredited investor" as that
      term is defined in CFR Section 230. 501(a) (Regulation D), as amended, of
      the SEC under the Securities Act. To be an accredited investor, an
      investor must fall within one of the categories set forth on Exhibit "C"
      attached hereto.

            7.11 Removal of Legends; Further Covenants.

                  7.11.1 Any legend placed on the Note, the Warrant or a
            Certificate pursuant to Section 7.8 hereof shall be removed (i) if
            the Note, the Warrant or the shares represented by such Certificates
            shall have been effectively registered under the Securities Act or
            otherwise lawfully sold in a public transaction, (ii) if the shares
            may be transferred in compliance with Rule 144(k) promulgated under
            the Securities Act, or (iii) if Lender shall have provided the
            Company with an opinion of counsel, in form and substance acceptable
            to the Company and its counsel and from attorneys reasonably
            acceptable to the Company and its counsel, stating that a public
            sale, transfer or assignment of the Note, the Warrant or the shares
            underlying the Warrant may be made without registration.

                  7.11.2 Any legend placed on the Note or a Certificate pursuant
            to Section 8.8 hereof shall be removed if the Company receives an
            order of the appropriate state authority authorizing such removal or
            if Lender provides the Company with an opinion of counsel, in form

                                       6

<PAGE>

            and substance acceptable to the Company and its counsel and from
            attorneys reasonably acceptable to the Company and its counsel,
            stating that such state legend may be removed.

                  7.11.3 Lender further covenants that Lender will not transfer
            the Note or the Warrant, in violation of the Securities Act, the
            Securities and Exchange Act of 1934, as amended (the "Exchange
            Act"), or the rules of the Commission promulgated thereunder,
            including Rule 144 under the Securities Act. Further, Lender agrees
            that Lender will not transfer the Note, the Warrant or any shares
            underlying the Warrant without the Company's prior consent, even if
            Lender is otherwise permitted to transfer them pursuant to this
            Agreement and all applicable law.

                  7.12 Risk Factors. The Lender agrees and acknowledges that
            there are risk factors related to, among other things, (i) the sale
            by the Company of the Note, and (ii) the Company's business and
            financial condition. Lender and his, her or its representatives
            acknowledge and agree that they have carefully reviewed the RISK
            FACTORS attached hereto as Exhibit "D" in their entirety. Such Risk
            Factors are incorporated herein by this reference. THE LENDER IS
            AWARE THAT HIS, HER OR ITS INVESTMENT IN THE NOTE IS A SPECULATIVE
            INVESTMENT THAT HAS LIMITED LIQUIDITY AND IS SUBJECT TO THE RISK OF
            COMPLETE LOSS. THE LENDER IS ABLE, WITHOUT IMPAIRING HIS, HER OR ITS
            FINANCIAL CONDITION, TO SUFFER A COMPLETE LOSS OF HIS, HER OR ITS
            INVESTMENT IN THE NOTE.

      8. Board of Directors. Immediately following the execution of this
Agreement, Richard Ullman, or a representative of the Ullman family, and Frank
Newman will be appointed to the Company's Board of Directors as outside
independent directors and shall be entitled to the standard option package
provided to the Company's outside directors.

      9. Miscellaneous.

            9.1 Notices. Any communications between the parties or notices
      provided for in this Agreement may be given by mailing them, first class,
      postage prepaid, to Lender at:

      Francis A. Newman
      Address:________________

      _________________________

      and to the Company at:

            Gender Sciences, Inc.
            10 West Forest Avenue
            Englewood, New Jersey  07631
            Attn: Eugene Terry

      With a copy to:

            Foley & Lardner
            402 West Broadway, 23rd Floor
            San Diego, California  92101
            Attn: Kenneth D. Polin

                                       7

<PAGE>

      or to such other address as either party may indicate to the other in
      writing after the date of this Agreement.

            9.2 Successors and Assigns. This Agreement shall bind and inure to
      the benefit of the parties and their respective successors and assigns;
      provided, however, that the Company shall not assign this Agreement or any
      of the rights, duties, or obligations of the Company under this Agreement
      without the prior written consent of Lender.

            9.3 Delay and Waivers. No delay or omission to exercise any right,
      power, or remedy accruing to Lender on any breach or default of the
      Company under this Agreement shall impair any such right, power, or remedy
      of Lender, nor shall it be construed to be a waiver of any such breach or
      default, or an acquiescence in such breach or default, or waiver of or
      acquiescence in any similar breach or default occurring later; nor shall
      any waiver of any single breach or default be considered a waiver of any
      other prior or subsequent breach or default. Any waiver, permit, consent,
      or approval of any kind by Lender of any breach or default under this
      Agreement, or any waiver by Lender of any provision or condition of this
      Agreement, must be in writing and shall be effective only to the extent
      specifically set forth in that writing. All remedies, either under this
      Agreement or by law or otherwise afforded to Lender, shall be cumulative
      and not alternative.

            9.4 Attorneys Fees. In the event of any legal action or suit in
      relation to this Agreement or any note or other instrument or agreement
      required under this Agreement, or in the event that Lender incurs any
      legal expense in protecting its rights under this Agreement or under any
      security agreement in any legal proceeding, the Company, in addition to
      all other sums which the Company may be called on to pay, will pay to
      Lender the amount of such legal expense and will, if Lender prevails in
      such action, pay to Lender a reasonable sum for its attorney's fees and
      all other costs and expenses.

            9.5 Severability. In the event any sentence or paragraph of this
      Agreement is declared void by a court of competent jurisdiction, said
      sentence or paragraph shall be deemed severed from the remainder of this
      Agreement, and the balance of this Agreement shall remain in effect.

            9.6 Titles, Captions and Paragraph Headings. Paragraph and
      subparagraph titles and captions contained in this Agreement are inserted
      only as a matter of convenience for reference. Such titles, captions, and
      paragraph headings in no way define, limit, extend or describe the scope
      of this Agreement or the intent of any provisions hereof.

            9.7 Number and Gender. Whenever a singular number is used in this
      Agreement or where required by context, the same shall include plural.
      Masculine gender shall include feminine and neuter genders and the word
      "person" shall include corporation, firm, partnership, or other forms of
      association.

            9.8 Entire Agreement. This Agreement constitutes the entire
      Agreement between all parties herein and supersedes all prior Agreements
      and understandings, oral or written, between the parties hereto with

                                       8

<PAGE>

      respect to the subject matter hereof, and shall not be modified or amended
      except in writing, executed by all parties herein.

            9.9 Counterparts. This Agreement may be executed in several
      counterparts, and as so executed shall constitute an Agreement, binding to
      all parties herein. Each counterpart may be signed and transmitted with
      the same validity as if it were an ink-signed document.

            9.10 Non-Waiver. No delay or omission on the part of any party
      herein in exercising any rights or remedies herein shall operate as a
      waiver of such rights or remedies. No waiver of any default shall
      constitute a waiver of any other default, whether of the same or any other
      covenant or condition. No waiver, benefit, privilege or service
      voluntarily given or performed by any party herein shall give the other
      parties any contractual right by custom, estoppel or otherwise. Any waiver
      by any party herein must be executed in writing, expressly specifying the
      subject and extent of the waiver.

            9.11 Governing Law and Venue. This Agreement and all amendments
      thereto shall be governed, construed, and enforced in accordance with the
      laws of the State of New Jersey.

            9.12 Legal Representation. The law firm of Foley & Lardner has
      prepared this Agreement solely on behalf of the Company based on
      instructions received. The Lender has been advised to seek and obtain
      separate legal counsel with respect to the preparation and execution of
      this Agreement, and he/she has had an opportunity to do so, has access to
      qualified independent counsel and has sought and obtained such advice and
      counsel to the extent desired.

            9.13 Construction. This Agreement has been negotiated between the
      parties and their advisors, and shall not be construed against the party
      preparing it, but shall be construed as if all parties jointly prepared
      this Agreement and any uncertainty and ambiguity shall not be interpreted
      against any one party.

            9.14 No Other Inducement. The making, execution and delivery of this
      Agreement by the parties hereto has been induced by no representations,
      statements, warranties or agreements other than those expressed herein.

            9.15 Disputes. In the event of an inconsistency arising between the
      terms of the Note or the Warrant and this Loan Agreement, the terms of the
      Loan Agreement shall control.

                    [Remainder of Page Intentionally Left Blank]

                                       9

<PAGE>

             IN WITNESS WHEREOF, the parties to this Agreement have executed
this loan Agreement by their duly authorized officers effective as of the day
                        and year first above written.

      "Company"                     Gender Sciences, Inc.,
                                    a New Jersey corporation

                                    /s/ EUGENE TERRY
                                    ------------------------------------
                                    Eugene Terry, Chairman

      "Lender"
                                    /s/ FRANCIS A. NEWMAN
                                    ------------------------------------
                                    Francis A. Newman

                       [Signature Page to Loan Agreement]

                                       10

<PAGE>

                                TABLE OF EXHIBITS

Exhibit "A"                   Form of Convertible Promissory Note

Exhibit "B"                   Form of Warrant

Exhibit "C"                   Definition of "accredited investor"

Exhibit "D"                   Risk Factors

Exhibit "E"                   Capitalization Table

                                  Exhibit List

<PAGE>

                                    EXHIBIT A

                                      NOTE

                                       A-1

<PAGE>

NEITHER THIS PROMISSORY NOTE NOR THE SHARES INTO WHICH IT IS CONVERTIBLE HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAW.
THE COMPANY WILL NOT TRANSFER THIS PROMISSORY NOTE OR THE UNDERLYING SHARES
UNLESS: (i) THERE IS AN EFFECTIVE REGISTRATION COVERING SUCH PROMISSORY NOTE OR
SUCH SHARES, AS THE CASE MAY BE, UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE
STATE SECURITIES LAWS, OR (ii) IT FIRST RECEIVES A LETTER FROM AN ATTORNEY,
ACCEPTABLE TO THE BOARD OF DIRECTORS OR ITS AGENTS, STATING THAT IN THE OPINION
OF THE ATTORNEY THE PROPOSED TRANSFER IS EXEMPT FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933 AND UNDER ALL APPLICABLE STATE SECURITIES LAWS.

                              GENDER SCIENCES, INC.
                           CONVERTIBLE PROMISSORY NOTE

$50,000                                                       November 5, 2002

      Gender Sciences, Inc., a New Jersey corporation (the "Company"), for value
received, hereby promises to pay to Francis A. Newman ("Lender"), on the
Maturity Date (as hereinafter defined), the principal amount of Fifty Thousand
Dollars ($50,000) plus accrued and unpaid interest thereon, at a simple interest
rate of Eight Percent (8%) per annum from the date hereof until the Maturity
Date. Unless converted into shares of the Company's capital stock, all sums due
pursuant to this Note shall be due and payable on the third (3rd) anniversary of
the date of this Note ("Maturity Date") at the principal office of the Company
at 10 West Forest Avenue, Englewood, New Jersey 07631 in currency of the United
States of America which at the time of payment shall be legal tender for payment
of public and private debts.

      This Note is made pursuant to a Loan Agreement of even date herewith. All
capitalized terms not otherwise defined herein shall have the meaning attributed
to them in the Loan Agreement. Any conflict between the Loan Agreement and this
Note shall be determined by the Loan Agreement.

      1. Waiver. The Company and any and each other person or entity liable for
the payment or collection of this Note expressly waives demand and presentment
for payment, notice of nonpayment, protest, notice of protest, notice of
dishonor, bringing of suit and diligence in taking any action to collect amounts
called for under this Note and in the handling of property at any time existing
as security in connection with this Note, and shall be directly and primarily
liable for the payment of all sums owing and to be owing on this Note,
regardless of and without any notice, diligence, act or omission as or with
respect to the collection of any amount called for under this Note.

      2. Costs of Collection. The Company agrees to pay all reasonable costs,
including reasonable attorneys' fees, incurred by the Lender in collecting or
enforcing payment of this Note in accordance with its terms.

<PAGE>

      3. Conversion.

            a. Voluntary Conversion. If not sooner converted as described in
      Section 3.2 below, all or some of the outstanding principal balance of,
      and all or some of the accrued and unpaid interest on, this Note may be
      converted at any time prior to the Maturity Date, at the option of the
      Lender, into shares of Common Stock of the Company at a conversion price
      per share equal to Five Cents ($0.05).

            b. Automatic Conversion. At the closing of a Qualifying Equity
      Financing (as defined below) on or before the Maturity Date, the entire
      outstanding principal balance of and all accrued and unpaid interest on,
      this Note shall be automatically converted into the number of shares of
      either (1) Preferred Stock or Common Stock, as the case may be, if the
      price per share in the Qualified Equity Financing is equal to or less than
      Five Cents ($0.05); or (2) Common Stock if the price per share is greater
      in the Qualified Equity Financing than Five Cents ($0.05), as is obtained
      by dividing (a) the outstanding principal balance of, and all accrued and
      unpaid interest on, the Note as of the closing date of the Qualified
      Equity Financing by (b) the lower of (i) Five Cents ($0.05) or (ii) the
      price per share of Common Stock or Preferred Stock, as the case may be,
      issued in the Qualified Equity Financing. A "Qualified Equity Financing"
      shall mean an equity financing in which the Company sells shares of Common
      Stock or Preferred Stock and obtains net proceeds (including conversion of
      all convertible notes in connection with the bridge financing) in an
      amount not less than Two Million Dollars ($2,000,000).

            c. Notice. If this Note is automatically converted as provided for
      in Section 3.2 above, written notice shall be delivered to the Lender at
      the address last shown on the records of the Company for the Lender or
      given by the Lender to the Company for the purpose of notice, or, if no
      such address appears or is given, at the place where the principal
      executive office of the Company is located, notifying the Lender of the
      conversion, specifying the principal amount of this Note converted, the
      amount of accrued and unpaid interest converted, the date of such
      conversion and calling upon the Lender to surrender this Note to the
      Company in exchange for equity securities of the Company as provided
      herein, in the manner and at the place designated by the Company.

            d. Certificate. As promptly as practicable after the conversion of
      this Note, the Company at its expense will issue and deliver to the
      Lender, upon surrender of this Note, a certificate or certificates for the
      number of full shares of equity securities issuable upon such conversion.
      No fractional shares shall be issued in connection with any conversion
      under this Note, but in lieu of such fractional shares, the Company shall
      round up the number of shares to be received upon conversion of this Note
      to the next whole share of stock.

      4. Usury Savings Clause. Notwithstanding any provision of this Note, the
Company shall not and will not be required to pay interest at a rate or any fee
or charge in an amount prohibited by applicable law. If interest or any fee or
charge payable on any date would be prohibited, then such interest, fee or
charge will be automatically reduced to the maximum amount that is not
prohibited. In the event that Lender receives payment of any interest, fee, or
charge that would cause the amount so received to exceed the maximum amount

                                       2

<PAGE>

permitted under applicable law, then, to the extent that the amount so received
exceeds the maximum amount permitted under applicable law: (a) in the first
instance, the amount received shall be applied to principal and (b) in the
second instance, in the event that the principal amount of this Note has been
paid in full, the remaining amount so received shall be deemed to be a loan from
the Company to Lender, repayable upon the demand of the Company with interest at
the legal rate from the date of Lender's receipt of each payment in excess
interest, fees, or charges.

      5. Representations of Lender.

            a. Acquisition for Personal Account. Lender represents and warrants
      that it is acquiring this Note and the Conversion Shares (as defined
      below) (the "Securities") solely for its account for investment and not
      with a view to or for sale or distribution of said Securities. Lender also
      represents that the entire legal and beneficial interests it may acquire
      in the Securities are being acquired for, and will be held for, Lender's
      account only.

            b. Securities Are Not Registered. Lender understands that the
      Securities have not been registered under the Securities Act of 1933, as
      amended (the "Act") on the basis that no distribution or public offering
      of the securities of the Company is to be effected. Lender realizes that
      the basis for the exemption may not be present if, notwithstanding its
      representations, Lender has a present intention of acquiring the
      securities for a fixed or determinable period in the future, selling (in
      connection with a distribution or otherwise), granting any participation
      in, or otherwise distributing the Securities. Lender has no such present
      intention.

            c. Accredited Investor. Lender is an "accredited investor" within
      the meaning of Securities and Exchange Commission ("SEC") Rule 501 of
      Regulation D, as presently in effect.

      6. Covenants of the Company.

            a. Authorization. All corporate action on the part of the Company,
      its directors and its stockholders necessary for the authorization,
      execution, delivery and performance of this Note by Company and the
      performance of the Company's obligations hereunder, including the issuance
      and delivery of this Note and the shares of equity securities issuable
      upon conversion of this Note ("Conversion Shares") and the reservation of
      the Conversion Shares has been taken or will be taken prior to the
      issuance of such Conversion Shares. This Note, when executed and delivered
      by the Company, shall constitute a valid and binding obligation of the
      Company enforceable in accordance with its terms, subject to laws of
      general application relating to bankruptcy, insolvency, the relief of
      debtors and, with respect to rights to indemnity, subject to federal and
      state securities laws. The Conversion Shares, when issued in compliance
      with the provisions of this Note, will be validly issued, fully paid and
      nonassessable and free of any liens or encumbrances.

            b. No Impairment. Except and to the extent as waived or consented to
      by Lender, the Company will not, by amendment of its Certificate of
      Incorporation or through any reorganization, transfer of assets,

                                       3

<PAGE>

      consolidation, merger, dissolution, issue or sale of securities or any
      other voluntary action, avoid or seek to avoid the observance or
      performance of any of the terms to be observed or performed hereunder by
      the Company, but will at all times in good faith assist in the carrying
      out of all the provisions of this Note and in the taking of all such
      action as may be necessary or appropriate in order to protect the
      conversion rights of Lender against impairment.

      7. Default. Each of the following events shall be an "Event of Default"
hereunder:

            a. the Company fails to pay timely any of the principal amount due
      under this Note or any accrued interest or other amounts due under this
      Note on the date the same becomes due and payable or within twenty (20)
      business days thereafter;

            b. the Company files any petition or action for relief under any
      bankruptcy, reorganization, insolvency or moratorium law or any other law
      for the relief of, or relating to, debtors, now or hereafter in effect, or
      makes any assignment for the benefit of creditors or takes any corporate
      action in furtherance of any of the foregoing; or

            c. an involuntary petition is filed against the Company (unless such
      petition is dismissed or discharged within ninety (90) days) under any
      bankruptcy statute now or hereafter in effect, or a custodian, receiver,
      trustee, assignee for the benefit of creditors (or other similar official)
      is appointed to take possession, custody or control of any property of the
      Company.

      Upon the occurrence of an Event of Default hereunder, all unpaid
      principal, accrued interest and other amounts owing hereunder shall, at
      the option of Lender, be immediately due, payable and collectible by
      Lender pursuant to applicable law.

      8. Miscellaneous

            a. The Company currently has enough authorized shares sufficient to
      effect the conversion of this Note. Notwithstanding the foregoing, the
      Company's current authorized shares are not sufficient to effect the
      conversion of this Note assuming full exercise and conversion of the
      Company's other outstanding options and convertible securities.
      Accordingly, the Company hereby covenants and agrees to expeditiously take
      such corporate action as may be necessary to amend the Company's Articles
      of Incorporation to increase its authorized but unissued shares of capital
      stock to the number of shares as shall be sufficient for the conversion of
      all of its outstanding options and convertible securities.

            b. The Company hereby agrees that no failure on the part of the
      Lender to exercise any power, right or privilege hereunder, or to insist
      upon prompt compliance with the terms hereof, shall constitute a waiver
      thereof.

            c. The Lender shall not be deemed, by any act of omission or
      commission, to have waived any of their rights or remedies hereunder
      unless such waiver is in writing and signed by the Lender, and then only
      to the extent specifically set forth in writing. A waiver with reference
      to one event shall not be construed and continuing or as a bar to or
      waiver of any right or remedy as to a subsequent event. No delay or

                                       4

<PAGE>

      omission of the Lender to exercise any right, whether before or after an
      event of default or a default thereunder, shall impair any such right or
      shall be construed to be a waiver of any right or default, and the
      acceptance at any time by the Lender of any past due amounts shall not be
      deemed to be a waiver of the right to require prompt payment when due of
      any other amounts then or thereafter due and payable.

            d. The remedies of the Lender in this Note or at law or in equity,
      shall be cumulative and concurrent, and may be pursued singly,
      successively or together at the sole discretion of the Lender, and may be
      exercised as often as occasion therefor shall occur; and the failure to
      exercise any such right or remedy shall in no event be construed as a
      waiver or release thereof.

            e. Lender shall not become or be deemed a partner or joint venturer
      with the Company by reason of any provisions of this Note.

            f. If any amount of principal or interest on or in respect of this
      Note becomes due and payable on any date which is not a Business Day, such
      amount shall be payable on the next preceding Business Day. "Business Day"
      means any day other than a Saturday, Sunday, statutory holiday or other
      day on which banks in the State of California are required by law to close
      or are customarily closed.

            g. If any of the provisions of this Note or the application thereof
      to any persons or circumstances shall, to any extent, be held to be
      invalid or unenforceable, the remainder of this Note by the application of
      such provision or provisions to persons or circumstances other than those
      as for whom or of which it is held invalid or unenforceable shall not be
      affected thereby, and every provision of this Note shall be valid and
      enforceable to the fullest extent permitted by law.

            h. The terms of this Note shall apply to, inure to the benefit of,
      and bind all parties hereto, their heirs, legatees, devisees,
      administrators, executors, successors, assigns or any entity formed as a
      result of the Company reincorporating in another jurisdiction.

            i. Time is of the essence of this Note and the performance of all
      provisions hereof.

            j. This Note is registered on the books of the Company and is
      transferable only by surrender thereof at the principal office of the
      Company duly endorsed or accompanied by a written instrument of transfer
      duly executed by the registered Lender of this Note or its attorney duly
      authorized in writing. Payment of or on account of principal and interest
      on this Note shall be made only to or upon the order in writing of the
      registered Lender.

            k. Note is governed by and construed in accordance with me laws or
      the State of New Jersey.

                                       5

<PAGE>

            l. The Lender will not be entitled to vote, receive dividends or
      exercise any of the rights of the holders of the Company's equity
      securities for any purpose prior to the conversion of this Note.

                 [Remainder of Page Intentionally Left Blank]

                                       6

<PAGE>

      "Company"                     Gender Sciences, Inc.,
                                    a New Jersey corporation

                                    /s/ EUGENE TERRY
                                    ------------------------------------
                                    Eugene Terry, Chairman

      "Lender"
                                    /s/ FRANCIS A. NEWMAN
                                    ------------------------------------
                                    Francis A. Newman

                                       7

<PAGE>

                                    EXHIBIT B

                                     WARRANT

                                       B-1

<PAGE>

VOID AFTER 5:00 P.M. EASTERN TIME ON NOVEMBER 5, 2005

NEITHER THIS WARRANT NOR THE WARRANT SHARES HAVE BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933. THE COMPANY WILL NOT TRANSFER THIS WARRANT OR THE
WARRANT SHARES UNLESS (i) THERE IS AN EFFECTIVE REGISTRATION COVERING SUCH
WARRANT OR SUCH WARRANT SHARES, AS THE CASE MAY BE, UNDER THE SECURITIES ACT OF
1933 AND APPLICABLE STATES SECURITIES LAWS, (ii) IT FIRST RECEIVES A LETTER FROM
AN ATTORNEY, ACCEPTABLE TO THE BOARD OF DIRECTORS AND ITS AGENTS, STATING THAT
IN THE OPINION OF THE ATTORNEY THE PROPOSED TRANSFER IS EXEMPT FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933 AND UNDER ALL APPLICABLE STATE SECURITIES LAWS,
OR (iii) THE TRANSFER IS MADE PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF
1933.

                              GENDER SCIENCES, INC.
                          COMMON STOCK PURCHASE WARRANT
                          -----------------------------

                                                        Warrant to Subscribe for
November 5, 2002                                1,000,000 Shares of Common Stock

                         Not Transferable or Exercisable
                     Except Upon Conditions Herein Specified
                     ---------------------------------------

      THIS CERTIFIES that, for value received, Francis A. Newman (such person or
entity and any successor and assign being hereinafter referred to as the
`Holder") is entitled to subscribe for and purchase from Gender Sciences, Inc.,
a New Jersey corporation (hereinafter called the "Company"), One Million
(1,000,000) shares of Common Stock, (the "Common Stock"), of the Company (such
shares to be subject to adjustment in accordance with Sections 1 and 5 hereof,
hereinafter sometimes called the "Warrant Shares") at an exercise price of Five
Cents ($0.05) per share as adjusted in accordance with Section 1 hereof (the
"Strike Price'), at any time or from time to time from the date hereof to and
including November _, 2005 (the "Exercise Period").

      1. Exercise of Warrant.

            1.1 The rights represented by this Warrant may be exercised by the
      Holder hereof, in whole at any time or in part from time to time during
      the Exercise Period, but not as to a fractional share of Common Stock, by
      the surrender of this Warrant (properly endorsed) at the principal office
      of the Company, at 10 West Forest Avenue, Englewood, New Jersey 07631 (or
      at such other agency or office of the Company in the United States of
      America as the Company may designate by notice in writing to the Holder
      hereof at the address of such Holder appearing on the books of the
      Company), and by payment to the Company of the Strike Price in cash or by
      certified or official bank check in United States Dollars for each share
      being purchased (the "Exercise Payment"); provided, however, that, at the

<PAGE>

      option of the Holder, the Exercise Payment may instead be satisfied by
      withholding from those Warrant Shares that would otherwise be obtained
      upon such exercise (the "Total Warrant Shares") a number of Warrant Shares
      having an aggregate Current Fair Market Value (as defined below) equal to
      the aggregate Strike Price that would otherwise have been payable for the
      Total Warrant Shares.

            1.2 In the event of any exercise of the rights represented by this
      Warrant, (i) a certificate or certificates for the shares of Common Stock
      so purchased, registered in the name of the person entitled to receive the
      same, shall be mailed to the Holder within a reasonable time after the
      rights represented by this Warrant shall have been so exercised; provided,
      however, that the Company shall not be required to pay any tax which may
      be payable in respect of any transfer involved in the issuance and
      delivery of any such certificate in a name other than that of the
      registered Holder thereof, and the Company shall not be required to issue
      or deliver such certificates unless or until the person or persons
      requesting the issuance thereof shall have paid to the Company the amount
      of such tax or shall have established to the satisfaction of the Company
      that such tax has been paid; and (ii) unless this Warrant has expired, a
      new Warrant representing the number of shares (except a remaining
      fractional share), if any, with respect to which this Warrant shall not
      then have been exercised shall also be issued to the Holder hereof within
      such time. The person in whose name any certificate for shares of Common
      Stock is issued upon exercise of this Warrant, shall for all purposes be
      deemed to have become the Holder of record of such shares on the date on
      which this Warrant was surrendered and payment of the Strike Price was
      made (unless the cashless exercise option described in the foregoing
      proviso is selected by the Holder), irrespective of the date of delivery
      of such certificate, except that, if the date of such surrender and
      payment is a date when the stock transfer books of the Company are closed,
      such person shall be deemed to have become the Holder of record of such
      shares at the close of business on the next succeeding date on which the
      stock transfer books are open. The issuance of any shares of Common Stock
      pursuant to the terms of this Warrant shall at all times be subject to
      compliance with all requirements of the Securities Act of 1933, as
      amended, and with all applicable foreign and state securities and blue sky
      laws then in effect. If the Holder elects to use the cashless exercise
      option described in Section 1.1 above to exercise this Warrant by
      withholding a portion of the Total Warrant Shares, this Warrant shall be
      terminated with respect to the number of Total Warrant Shares withheld.

            1.3 Current Fair Market Value. For the purposes of this Warrant, the
      "Current Fair Market Value" of each share of Common Stock shall be
      determined as follows:

                  1.3.1 If the Common Stock is listed on a national securities
            exchange or admitted to unlisted trading privileges on such an
            exchange, the Current Fair Market Value shall be the average of the
            last reported sale prices of the Common Stock on such exchange based
            on the last thirty (30) Business Days (as defined below) prior to
            the date of exercise of this Warrant, or, if the Common Stock is not
            so listed or admitted to unlisted trading privileges on a national
            securities exchange but is listed on NASDAQ, the Current Fair Market
            Value shall be the average of the last reported sale prices of the
            Common Stock on NASDAQ based on the last thirty (30) Business Days
            prior to the date of exercise of this Warrant; or

                  1.3.2 If the Common Stock is not so listed or admitted to
            unlisted trading privileges on a national securities exchange or

                                      -2-
<PAGE>

            quoted on NASDAQ, the Current Fair Market Value shall be the average
            mean of the last closing bid and asked prices reported on the last
            five (5) Business Days prior to the date of exercise of this Warrant
            (x) by NASDAQ, or (y) if reports are unavailable under clause (x)
            above, by the National Quotation Bureau Incorporated ("NAB"); or

                  1.3.3 If the Common Stock is not so listed or admitted to
            unlisted trading privileges on a national securities exchange and
            bid and asked prices are not so reported by NASDAQ or NAB, the
            Current Fair Market Value shall be an amount per share, determined
            in such reasonable manner as may be prescribed by the Company's
            Board of Directors in good faith.

                  1.3.4 As used in this Section 3, "Business Day" means any day
            other than a Saturday or Sunday on which the relevant exchange,
            system or service is open or available, as the case may be.

            1.4 Adjustments in Number and Strike Prices of Warrant Shares. If,
      pursuant to the Qualifying Equity Financing (as defined below), the
      Company sells (i) Common Stock at a price per share less than the Strike
      Price, then the Company shall exchange this Warrant for a warrant to
      purchase the same number of shares of Common Stock at a price per share
      equal to the price per share offered in the Qualifying Equity Financing;
      or (ii) Preferred Stock at a price per share equal to or less than the
      Strike Price, then the Company shall exchange the Warrant for warrant to
      purchase the same number of shares of Preferred Stock at a price per share
      equal to the price per share offered in the Qualifying Equity Financing. A
      "Qualified Equity Financing" shall mean an equity financing in which the
      Company sells shares of Common Stock or Preferred Stock and obtains net
      proceeds (including conversion of all convertible notes in connection with
      a bridge financing) in an amount not less than Two Million Dollars
      ($2,000,000).

            1.5 Covenants as to Common Stock. The Company covenants and agrees
      all Warrant Shares will, upon issuance, be validly issued, fully paid and
      nonassessable, and free from all taxes, liens and charges with respect to
      the issue thereof. The Company currently has enough authorized shares
      sufficient to effect the exercise of this Warrant. Notwithstanding the
      foregoing, the Company's current authorized shares are not sufficient to
      effect the exercise of this Warrant assuming full exercise and conversion
      of the Company's other outstanding options and convertible securities.
      Accordingly, the Company hereby covenants and agrees to expeditiously take
      such corporate action as may be necessary to amend the Company's Articles
      of Incorporation to increase its authorized but unissued shares of capital
      stock to the number of shares as shall be sufficient for the conversion of
      all of its outstanding options and convertible securities. If and so long
      as the Common Stock issuable upon the exercise of this Warrant is listed
      on any national securities exchange, the Company will, if permitted by the
      rules of such exchange, list and keep listed on such exchange, upon
      official notice of issuance, all of the Warrant Shares.

      2. Transfer.

            2.1 Securities Laws. Neither this Warrant nor the Warrant Shares
      have been registered under the Securities Act of 1933. The Company will
      not transfer this Warrant or the Warrant Shares unless (i) there is an

                                      -3-
<PAGE>

      effective registration covering such Warrant or such shares, as the case
      may be, under the Securities Act of 1933 and applicable states securities
      laws, (ii) it first receives a letter from an attorney, acceptable to the
      Company's board of directors or its agents, stating that in the opinion of
      the attorney the proposed transfer is exempt from registration under the
      Securities Act of 1933 and under all applicable state securities laws, or
      (iii) the transfer is made pursuant to Rule 144 under the Securities Act
      of 1933.

            2.2 Compliance With Blue Sky Laws. The Company will be able to issue
      the Warrant Shares upon exercise of the Warrant only if there is a then
      current Offering Memorandum or registration statement available for and
      distributed to the Warrant Holders relating to such Common Stock, and only
      if such Warrant and Common Stock is qualified for sale or exempt from
      qualification under applicable state securities laws of the jurisdiction
      in which the Holders of the Warrants reside. The Company reserves the
      right in its sole discretion to determine not to apply for exemptions or
      to register such Common Stock in any jurisdiction where the time and
      expense do not justify the costs of such exemption filing or registration.
      The Warrants may be deprived of any value in the event the Company does
      not satisfy or the Company chooses not to satisfy any such requirements.
      Although it is the present intention of the Company to satisfy such
      requirements, there can be no assurance the Company will be able to do so;
      provided, however, the Company will not be permitted to accelerate the
      termination of the Exercise Period of these Warrants unless such
      acceleration is accomplished in full compliance with Section 1 hereof.

            2.3 Investment Representations. The Holder of the Warrant agrees and
      acknowledges the Warrant is being purchased for his own account, for
      investment purposes only, that he, she or it either has a prior personal
      or business relationship with the officers, directors or controlling
      persons, or by reason of his business or financial experience, or the
      business or financial experience of he and his professional advisors who
      are unaffiliated with and not compensated by the Company, could be
      reasonably assumed to have the capacity to protect his, her or its own
      interests in connection with the purchase of and the exercise of the
      Warrants, and not for the account of any other person, and not with a view
      to distribution, assignment or resale to others or to fractionalization in
      whole or in part, and the Holder further represents, warrants and agrees
      as follows: no other person has or will have a direct or indirect
      beneficial interest in this Warrant and the Holder will not sell,
      hypothecate or otherwise transfer his Warrant except in accordance with
      the Act and applicable state securities laws or unless, in the opinion of
      counsel for the Holder acceptable to the Company, an exemption from the
      registration requirements of the Securities Act and such state laws is
      available.

            2.4 Conditions to Transfer. Prior to any such proposed transfer, and
      as a condition thereto, if such transfer is not made pursuant to an
      effective registration statement under the Securities Act, the Holder
      will, if requested by the Company, deliver to the Company (i) an
      investment covenant signed by the proposed transferee, (ii) an agreement
      by such transferee that the restrictive investment legend set forth above
      be placed on the certificate or certificates representing the securities
      acquired by such transferee, (iii) an agreement by such transferee that
      the Company may place a "stop transfer order" with its transfer agent or
      registrar, and (iv) an agreement by the transferee to indemnify the
      Company to the same extent as set forth in the next succeeding paragraph.

                                      -4-
<PAGE>

            2.5 Indemnity. The Holder acknowledges the Holder understands the
      meaning and legal consequences of this Section, and the Holder hereby
      agrees to indemnify and hold harmless the Company, its representatives and
      each officer, director, agent, and legal counsel thereof from and against
      any and all loss, damage or liability (including all attorneys' fees and
      costs incurred in enforcing this indemnity provision) due to or arising
      out of (a) the inaccuracy of any representation or the breach of any
      warranty of the Holder contained in, or any other breach of, this Warrant,
      (b) any transfer of any of this Warrant or the Warrant Shares in violation
      of the Securities Act of 1933, the Securities Exchange Act of 1934, as
      amended, or the rules and regulations promulgated under either of such
      acts, (c) any transfer of this Warrant or any of the Warrant Shares not in
      accordance with this Warrant or (d) any untrue statement or omission to
      state any material fact in connection with the investment representations
      or with respect to the facts and representations supplied by the Holder to
      counsel to the Company upon which its opinion as to a proposed transfer
      shall have been based.

            2.6 Holdback Period and Transfer. Except as specifically restricted
      hereby, this Warrant and the Warrant Shares issued may be transferred by
      the Holder in whole or in part at any time or from time to time. Upon
      surrender of this Warrant certificate to the Company or at the office of
      its stock transfer agent, if any, with the Assignment Form annexed hereto
      duly executed and funds sufficient to pay any transfer tax, and upon
      compliance with the foregoing provisions, the Company shall, without
      charge, execute and deliver a new Warrant certificate in the name of the
      assignee named in such instrument of assignment, and this Warrant
      certificate shall promptly be canceled. Any assignment, transfer, pledge,
      hypothecation or other disposition of this Warrant attempted contrary to
      the provisions of this Warrant, or any levy of execution, attachment or
      other process attempted upon this Warrant, shall be null and void and
      without effect.

      3. Rights of the Holder. The Holder shall not, by virtue hereof, be
entitled to any rights of a stockholder in the Company, either at law or in
equity, and the rights of the Holder are limited to those expressed in this
Warrant.

      4. Anti-Dilution Provisions.

            4.1 Stock Splits, Dividends, Etc.

                  4.1.1 If the Company shall at any time after the date hereof
            subdivide its outstanding shares of Common Stock (or other
            securities at the time receivable upon the exercise of the Warrant)
            by recapitalization, reclassification or split-up thereof, or if the
            Company shall declare a stock dividend or distribute shares of
            Common Stock to its stockholders, the number of shares of Common
            Stock subject to this Warrant immediately prior to such subdivision
            shall be proportionately increased, and if the Company shall at any
            time combine the outstanding shares of Common Stock by
            recapitalization, reclassification or combination thereof, the
            number of shares of Common Stock subject to this Warrant immediately
            prior to such combination shall be proportionately decreased. Any
            such adjustment to the Strike Price pursuant to this Section shall
            be effective at the close of business on the effective date of such
            subdivision or combination or if any adjustment is the result of a
            stock dividend or distribution then the effective date for such
            adjustment based thereon shall be the record date therefor.

                                      -5-
<PAGE>

                  4.1.2 Whenever the number of shares of Common Stock
            purchasable upon the exercise of this Warrant is adjusted, as
            provided in this Section, the Strike Price shall be adjusted to the
            nearest cent by multiplying such Strike Price immediately prior to
            such adjustment by a fraction (x) the numerator of which shall be
            the number of shares of Common Stock purchasable upon the exercise
            immediately prior to such adjustment, and (y) the denominator of
            which shall be the number of shares of Common Stock so purchasable
            immediately thereafter.

            4.2 Adjustment for Reorganization, Consolidation, Merger, Etc. In
      case of any reorganization of the Company (or any other corporation, the
      securities of which are at the time receivable on the exercise of this
      Warrant) after the date hereof, or in case after such date the Company (or
      any such other corporation) shall consolidate with or merge into another
      corporation or convey all or substantially all of its assets to another
      corporation, then, and in each such case, the Holder of this Warrant upon
      the exercise as provided in Section 1 above at any time after the
      consummation of such reorganization, consolidation, merger or conveyance,
      shall be entitled to receive, in lieu of the securities and property
      receivable upon the exercise of this Warrant prior to such consummation,
      the securities or property to which such Holder would have been entitled
      upon such consummation if such Holder had exercised this Warrant
      immediately prior thereto; in each such case, the terms of this Warrant
      shall be applicable to the securities or property received upon the
      exercise of this Warrant after such consummation.

            4.3 Certificate as to Adjustments. In each case of an adjustment in
      the number of shares of Common Stock receivable on the exercise of this
      Warrant, the Company at its expense shall promptly compute such adjustment
      in accordance with the terms of the Warrant and prepare a certificate
      executed by an officer of the Company setting forth such adjustment and
      showing the facts upon which such adjustment is based. The Company shall
      forthwith mail a copy of each such certificate to each Holder.

            4.4 Notices of Record Date, Etc. In case:

                  4.4.1 the Company shall take a record of the holders of its
            Common Stock (or other securities at the time receivable upon the
            exercise of the Warrant) for the purpose of entitling them to
            receive any dividend (other than a cash dividend at the same rate as
            the rate of the last cash dividend theretofore paid) or other
            distribution, or any right to subscribe for, purchase or otherwise
            acquire any shares of stock of any class or any other securities, or
            to receive any other right; or

                  4.4.2 of any voluntary or involuntary dissolution, liquidation
            or winding-up of the Company, then, and in each such case, the
            Company shall mail or cause to be mailed to each Holder a notice
            specifying, as the case may be, (A) the date on which a record is to
            be taken for the purpose of such dividend, distribution or right,
            and stating the amount and character of such dividend, distribution
            or right, or (B) the date on which such reorganization,
            reclassification, consolidation, merger, conveyance, dissolution,
            liquidation or winding-up is to take place, and the time, if any, to
            be fixed, as to which the holders of record of Common Stock (or such
            other securities at the time receivable upon the exercise of this
            Warrant) shall be entitled to exchange their shares of Common Stock
            (or such other securities) for securities or other property
            deliverable upon such reorganization, reclassification,

                                      -6-
<PAGE>

            consolidation, merger, conveyance, dissolution, liquidation or
            winding-up. Such notice shall be mailed at least twenty (20) days
            prior to the date therein specified, and this Warrant may be
            exercised prior to said date during the term of the Warrant.

            4.5 Threshold for Adjustments. Anything in this Section to the
      contrary notwithstanding, the Company shall not be required to give effect
      to any adjustment until the cumulative resulting adjustment in the Strike
      Price pursuant to this Section shall have required a change of the Strike
      Price by at least $0.10. No adjustment shall be made by reason of the
      issuance of shares upon conversion rights, stock issuance rights or
      similar rights currently outstanding or any change in the number of
      treasury shares held by the Company.

      5. Legend and Stop Transfer Orders. Unless the Warrant Shares have been
registered under the Securities Act, upon exercise of any of this Warrant and
the issuance of any of the Warrant Shares, the Company shall instruct its
transfer agent, if any, to enter stop transfer orders with respect to such
shares, and all certificates representing shares of Warrant Shares shall bear on
the face thereof substantially the following legend:

            This certificate has not been registered under the
            Securities Act of 1933. The Company will not transfer this
            certificate unless (i) there is an effective registration
            covering the shares represented by this certificate under
            the Securities Act of 1933 and all applicable state
            securities laws, (ii) it first receives a letter from an
            attorney, acceptable to the board of directors or its
            agents, stating that in the opinion of the attorney the
            proposed transfer is exempt from registration under the
            Securities Act of 1933 and under all applicable state
            securities laws, (iii) the transfer is made pursuant to
            Rule 144 under the Securities Act of 1933.

      6. Officer's Certificate. Whenever the number or kind of securities
purchasable upon exercise of this Warrant or the Strike Price shall be adjusted
as required by the provisions hereof, the Company shall forthwith file with its
Secretary or Assistant Secretary at its principal office and with its stock
transfer agent, if any, an officer's certificate showing the adjusted number of
kind of securities purchasable upon exercise of this Warrant and the adjusted
Strike Price determined as herein provided and setting forth in reasonable
detail such facts as shall be necessary to show the reason for and the manner of
computing such adjustments. Each such officer's certificate shall be made
available at all reasonable times for inspection by the Holder and the Company
shall, forthwith after each such adjustment, mail by certified mail a copy of
such certificate to the Holder.

      7. Transfer of Warrant. Subject to Section 3 hereof, this Warrant and all
rights hereunder are transferable in whole (or in part), at the agency of office
of the Company referred to in Section 1 hereof by the Holder hereof in person or
by duly authorized attorney, upon surrender of this Warrant properly endorsed.
Each taker and Holder of this Warrant, by taking or holding the same, consents
and agrees that this Warrant, when endorsed, in blank, shall be deemed
negotiable, and, when so endorsed the Holder hereof may be treated by the
Company and all other persons dealing with this Warrant as the absolute owner

                                      -7-
<PAGE>

hereof for all purposes and as the person entitled to exercise the rights
represented by this Warrant, or to the transfer hereof on the books of the
Company, any notice to the contrary notwithstanding; but until each transfer on
such books, the Company may treat the registered Holder hereof as the owner
hereof for all purposes.

      8. Elimination of Fractional Interests. The Company shall not be required
to issue stock certificates representing fractions of shares of Common Stock,
nor shall it be required to issue script or pay cash in lieu of fractional
interests, it being the intent of the parties that all fractional interests
shall be eliminated.

      9. Exchange of Warrant. Subject to the limitations set forth herein this
Warrant is exchangeable, upon the surrender hereof by the Holder hereof at the
office or agency of the Company designated in Section 1 hereof, for a new
Warrant of like tenor representing the right to subscribe for and purchase the
number of Warrant Shares which may be subscribed for and purchased hereunder.

      10. Notices to Warrant Holders. Nothing contained in this Warrant shall be
construed as conferring upon the Holder hereof the right to vote or to consent
to or receive notice as a shareholder in respect of any meetings of shareholders
for the election of Directors or any other matter, or as having any rights
whatsoever as a shareholder of the Company. If, however, at any time prior to
the expiration of the Warrant and prior to its exercise, any of the following
events shall occur:

            10.1 The Company shall offer to all of the holders of its Common
      Stock any additional shares of stock of the Company or securities
      convertible into or exchangeable for shares of stock of the Company, or
      any option, right or warrant to subscribe therefor; or

            10.2 A dissolution, liquidation or winding up of the Company (other
      than in connection with a consolidation or merger) or a sale of all or
      substantially all of its property, assets and business as an entirety
      (whether by merger, consolidation or sale of assets) shall be proposed;
      then, in any one or more of said events, the Company shall give written
      notice of such events at least fifteen (15) days prior to the date fixed
      as a record date or the date of closing the transfer books for the
      determination of the shareholders entitled to such convertible or
      exchangeable securities or subscription rights, or entitled to vote on
      such proposed dissolution, liquidation, winding up or sale. Such notice
      shall specify such record date or the date of closing the transfer books,
      as the case may be. Failure to give such notice or any defect therein
      shall not affect the validity of any action taken in connection with the
      issuance of any convertible or exchangeable securities, or subscription
      rights, options or warrants, or any proposed dissolution, liquidation,
      winding up or sale.

      11. Lost, Stolen, Mutilated or Destroyed Warrant. Upon surrender by the
Holder of this Warrant to the Company, the Company at its expense will issue in
exchange therefor, and deliver to such Holder, a new Warrant. Upon receipt of
evidence satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant, and in the case of any such loss, theft or
destruction, upon delivery by such Holder of an indemnity agreement or security
satisfactory to the Company, and in case of any such mutilation, upon surrender
and cancellation of this Warrant, the Company, upon reimbursement of all

                                      -8-
<PAGE>

reasonable expenses incident thereto, will issue and deliver to such Holder a
new Warrant of like tenor, in lieu of such lost, stolen, destroyed or mutilated
Warrant. Any Warrant delivered to such Holder in accordance with this Section 11
shall bear the same securities legends as the Warrant which it replaced.

      12. Governing Law. This Warrant shall be governed by, and construed in
accordance with, the laws of the State of New Jersey applicable to contracts
made therein.

      13. Notices. Any communications between the parties or notices provided
for in this Agreement may be given by mailing them, first class, postage
prepaid, to Holder at:

      Francis A. Newman
      Address:________________

      _________________________

and to the Company at:

      Gender Sciences, Inc.
      10 West Forest Avenue
      Englewood, New Jersey  07631
      Attn: Eugene Terry

With a copy to:

      Foley & Lardner
      402 West Broadway, 23rd Floor
      San Diego, California  92101
      Attn: Kenneth D. Polin

or to such other address as either party may indicate to the other in writing
after the date of this Agreement.

      14. Successors. All the covenants, agreements, representations and
warranties contained in this Warrant shall bind the parties hereto and their
respective heirs, executors, administrators, distributees, successors and
assigns.

      15. Headings. The Article and Section headings in this Warrant are
inserted for purposes of convenience only and shall have no substantive effect.

                 [Remainder of Page Intentionally Left Blank]

                                      -9-
<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by
a duly authorized officer under its corporate seal and to be dated as of the
date first above written.

"Company"                        Gender Sciences, Inc., a New Jersey corporation

                                 /s/ EUGENE TERRY
                                 ------------------------------------
                                 Eugene Terry, Chairman

"Holder"
                                 /s/ FRANCIS A. NEWMAN
                                 ------------------------------------
                                 Francis A. Newman

                           [Signature Page to Warrant]

                                      -10-
<PAGE>

                               FORM OF ASSIGNMENT

[To be signed only upon transfer of the Warrant]

      FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ___________________, all of the rights represented by the within Warrant to
purchase ___________________ shares of Common Stock of Gender Sciences, Inc. to
which the within Warrant relates, and appoints Kenneth D. Polin as the attorney
to transfer such rights on the books of Gender Sciences, Inc. with full power of
substitution in the premises.

Dated

-------------------------------              -------------------------------
                                                     (Signature)

                                             -------------------------------

                                             -------------------------------
                                                     (Address)

Notarization Required:

<PAGE>

                                FORM OF EXERCISE

[To be signed only upon exercise of the Warrant]

      THE UNDERSIGNED, the Holder of the within Warrant, hereby irrevocably
elects to exercise the purchase right represented by such Warrant for, and to
purchase thereunder, __________ shares of Common Stock of Gender Sciences, Inc.
and herewith tenders payment of $______________ in full payment of the exercise
price for such shares, and requests that the certificates for such shares be
issued in the name of, and delivered to, _________________________ whose address
is ______________________________________

Dated

-------------------------------              -------------------------------
                                                     (Signature)

                                             -------------------------------

                                             -------------------------------
                                                     (Address)

<PAGE>

                                    EXHIBIT C

                       Definition of "accredited investor"

Individuals:

      *     An individual who, together with your spouse, has a net worth in
            excess of $1,000,000 (including home, furnishings and automobiles).

      *     An individual who had gross income in excess of $200,000, or joint
            income with spouse in excess of $300,000, for each of the last two
            years and reasonably expects to have gross income of $200,000, or
            joint income in excess of $300,000, for the current year.

      *     A director or executive officer of the Company

Entities:

      *     A bank as defined in Section 3(a)(2) of the Securities Act of 1933
            (the "Act"), or any savings and loan association defined in Section
            3(a)(5)(A) of the Act, whether acting in its individual or fiduciary
            capacity; any broker-dealer registered pursuant to Section 15 of the
            Securities Exchange Act of 1934; insurance company as defined in
            Section 2(13) of the Act; investment company registered under the
            Investment Company Act of 1940 or a business development company as
            defined in Section 2(a)(48) of that Act; Small Business Investment
            Company licensed by the U.S. Small Business Administration under
            Section 301(c) or (d) of the Small Business Investment Act of 1958.

      *     An employee benefit plan within the meaning of Title I of the
            Employee Retirement Income Security Act, if investment decisions are
            made by a plan fiduciary, as defined in Section 3(21) of that act,
            which is either a bank, savings and loan association, insurance
            company, or registered investment advisor, or if the employee
            benefit plan has total assets in excess of $5,000,000.

      *     A self-directed employee benefit plan within the meaning of Title I
            of the Employee Retirement Income Security Act of 1974, whose
            investment decisions are made solely by accredited investors.

      *     Any private business development company as defined in Section
            202(a)(22) of the Investment Advisors Act of 1940.

      *     Any organization described in Section 501(c)(3) of the Internal
            Revenue Code, corporation, Massachusetts or similar business trust,
            or partnership, not formed for the specific purpose of making this
            investment, with total assets in excess of $5,000,000.

      *     Any trust with total assets in excess of $5,000,000 not formed for
            the specific purpose of acquiring securities offered by the Company,
            if the investment is directed by a person who has such knowledge and
            experience in financial and business matters that he or she is
            capable of evaluating the merits and risks of the proposed
            investment.

      *     Any entity in which all of the equity owners individually qualify as
            accredited investors.

                                       C-1
<PAGE>

                                   EXHIBIT "D"

                                  RISK FACTORS

An investment in the Company is highly speculative and subject to a high degree
of risk. Only those investors who can bear the risk of the entire loss of their
investment should participate. You should carefully consider the risks described
below, in addition to the other information in these materials, before making an
investment in the securities. The risks and uncertainties described below are
not the only ones facing the Company. Additional risks and uncertainties not
presently known to the Company or that it currently considers immaterial may
also impair its operations. If any of the following risks actually occur, the
Company's business, financial condition or results of operations could be
materially adversely affected. In that case, the value of your investment could
decline, and you may lose all or part of your investment.

      1. RISKS RELATED TO THE COMPANY'S BUSINESS AND FINANCIAL CONDITION

            1.1 Need for Additional Financing

      The Company will need to raise additional capital to continue its
activities and operations (the "Additional Financing"). The failure to obtain
Additional Financing will seriously jeopardize the Company's ability to continue
as a going concern. Accordingly, the Company will require Additional Financing
for its operations and there can be no assurance that the Company will be able
to acquire Additional Financing on favorable terms, or at all. The Company may
seek Additional Financing through public or additional private debt or equity
offerings. Providers of Additional Financing may require repayment, interest,
fees or other payments from revenues derived from the Company's products and
services distribution and other exploitation which may significantly reduce
revenues and/or profits generated by the Company. In addition, Additional
Financing may be senior to the Convertible Promissory Notes (the "Convertible
Notes") offered by the Company. There are no guarantees that attempts to secure
any such Additional Financing will be successful. Other financing needs may also
arise and no assurance can be given that the Company will be able to meet such
needs as they arise.

      If adequate funds are not available or are not available on acceptable
terms, the Company might not be able to take advantage of unanticipated
opportunities, develop new products or services or otherwise respond to
unanticipated competitive pressures.

            1.2 Significant Amount of Revenues Generated From Single Customer.

      For the fiscal year ended January 31, 2002, one customer accounted for
approximately 32% of the Company's total revenues. The Company does not have a
contract with this customer and, as a result, there is no assurance that this
customer will continue to order products from the Company or will continue to
order the products in the same amount. The loss of this customer would have a
material effect upon the operation of the Company.

                                      D-1
<PAGE>

            1.3 The Company has recently instituted its new business strategy.
      Its business must expand for it to attain profitability.

      The Company has only recently commenced the implementation of its new
business strategy. The Company may not successfully complete the transition to
successful operations or profitability pursuant to its new strategy. The Company
may encounter problems, delays and expenses in implementing its new business
strategy. These may include, but not be limited to, unanticipated problems and
13 additional costs related to marketing, competition and product acquisitions
and development. These problems may be beyond the Company's control, and in any
event, could adversely affect the Company's results of operations.

            1.4 If the Company Does Not Successfully Manage Any Growth It
      Experiences, it May Experience Increased Expenses without Corresponding
      Revenue Increases.

      The Company's business plan will, if implemented, result in expansion of
its operations. This expansion may place a significant strain on management,
financial and other resources. It also will require the Company to increase
expenditures before it generates corresponding revenues. The Company's ability
to manage future growth, should it occur, will depend upon its ability to
identify, attract, motivate, train and retain highly skilled managerial,
financial, business development, sales and marketing and other personnel.
Competition for these employees is intense. Moreover, the addition of products
or businesses will require the Company's management to integrate and manage new
operations and an increasing number of employees. The Company may not be able to
implement successfully and maintain its operational and financial systems or
otherwise adapt to growth. Any failure to manage growth, if attained, would have
a material adverse effect on the Company's business. The Company, due to its
limited capital presently has only three full time employees which creates an
additional risk that the Company may not be successful in implementing its
strategy.

            1.5 The Company is Dependent an a Limited Number of Sources of
      Supply for Many of the Products it Offers. If One of its Suppliers Fails
      to Supply Adequate Amounts of a Product the Company Offers, the Company's
      Sales May Suffer and it Could Be Required to Abandon a Product Line.

      The Company is dependent on a limited number of sources of supply for many
of the products it offers. With respect to these products, the Company cannot
guarantee that these third parties will be able to provide adequate supplies of
products in a timely fashion. The Company also faces the risk that one of its
suppliers could become insolvent, declare bankruptcy, lose its production
facilities in a disaster, be unable to comply with applicable government
regulations or lose the governmental permits necessary to manufacture the
products it supplies to the Company. If the Company is unable to renew or extend
an agreement with a third-party supplier, if an existing agreement is terminated
or if a third-party supplier otherwise cannot meet the Company's need for a
product, the Company may not be able to obtain an alternative source of supply

                                      D-2
<PAGE>

in a timely manner or at all. In these circumstances, the Company may be unable
to continue to market products as planned and could be required to abandon or
divest itself of a product line on terms which would materially affect it.

            1.6 The Company May Be Exposed To Product Liability Claims Not
      Covered By Insurance That Would Harm its Business.

      The Company may be exposed to product liability claims. Although the
Company believes that it currently carries and intends to maintain a
comprehensive multi peril liability package, the Company cannot guarantee that
this insurance will be sufficient to cover all possible liabilities. A
successful suit against the Company could have an adverse effect on its business
and financial condition if the amounts involved are material.

            1.7 The Company is Uncertain of its Ability to Obtain Additional
      Financing for its Future Capital Needs. If the Company is Unable to Obtain
      Additional Financing, it May Not Be Able to Continue to Operate its
      Business.

      The Company will require significant amounts of additional capital to
achieve its stated goals. The Company believes that the net proceeds from the
Company's recent private offering of common stock will not be sufficient to
completely implement its strategy in calendar year 2002. The Company's future
capital requirements will depend on many factors including: (i) the costs of its
sales and marketing activities and its education programs for its markets, o
competing product and market developments, (ii) the costs of acquiring or
developing new products,(iii) the costs of expanding its operations, and (iv)
its ability to generate positive cash flow from its sales.

      Additional funding may not be available on acceptable terms, if at all. If
adequate funds are not available, the Company may be required to curtail
significantly or defer one or more of its marketing programs or to limit or
postpone obtaining new products through license, acquisition or other
agreements. If the Company raises additional funds through the issuance of
equity securities, the percentage ownership of its then-current stockholders may
be reduced and such equity securities may have rights, preferences or privileges
senior to those of the holders of its common stock. If the Company raises
additional funds through the issuance of additional debt securities, these new
securities would have certain rights, preferences and privileges senior to those
of the holders of its common stock, and the terms of these debt securities could
impose restrictions on its operations.

            1.8 Going Concern Qualification Contained In Report of Independent
      Auditors.

      The Company has received from its auditors a report that raises
substantial doubt about its ability to continue as a going concern. If the
Company fails to raise additional funds or its new operating plan is not
successful, an investor in the Company could lose his entire investment.

                                      D-3
<PAGE>

            1.9 The Company's Inability to Obtain New Proprietary Rights or to
      Protect and Retain its Existing Rights Could Impair its Competitive
      Position and Adversely Affect its Sales.

      The Company believes that the trademarks, copyrights and other proprietary
rights that it owns or licenses, or that it will own or license in the future,
will continue to be important to its success and competitive position. If the
Company fails to maintain its existing rights or cannot acquire additional
rights in the future, its competitive position may be harmed. While some
products we offer incorporate patented technology, most of the products we sell
are not protected by patents. The Company intends to take the actions that it
believes are necessary to protect its proprietary rights, but it may not be
successful in doing so on commercially reasonable terms, if at all. In addition,
parties that license their proprietary rights to the Company may face challenges
to their patents and other proprietary rights and may not prevail in any
litigation regarding those rights. Moreover, the Company's trademarks and the
products it offers may conflict with or infringe upon the proprietary rights of
third parties. If any such conflicts or infringements should arise, the Company
would have to defend itself against such challenges. The Company also may have
to obtain a license to use those proprietary rights or possibly cease using
those rights altogether. Any of these events could harm the Company's business.

            1.10 If the Marketing Companies Do Not Successfully Sell the
      Products the Company Offers, the Company May Experience Significant
      Losses.

      The products the Company offers may not achieve market acceptance. The
market acceptance of these products will depend on, among other factors, their
advantages over existing competing products, and their perceived efficacy and
safety. The Company's business model assumes that the marketing programs
instituted by the marketing companies with which it has alliances will result in
increased demand for the products it offers. If the marketing programs do not
succeed in generating a substantial increase in demand for its products, the
Company will be unable to realize its operating objectives. In addition, the
Company's business model seeks to build on the expanding roles of marketing
partners, and its marketing efforts are concentrated on these groups. If these
distribution companies do not successfully sell the products the Company offers
or if their customers do not regularly use these products, the Company may
experience significant losses and its business will be adversely affected.

            1.11 The Health Care Industry and The Markets for the Products the
      Company Offers are Very Competitive. The Company May Not Be Able to
      Compete Effectively, Especially Against Established Industry Competitors
      with Significantly Greater Financial Resources.

      The health care industry is highly competitive. Many of the Company's
competitors are large well-known health care companies that have considerably
greater financial, sales, marketing and technical resources than the Company.
Additionally, these competitors have research and development capabilities that
may allow them to develop new or improved products that may compete with product
lines the Company markets and distributes. In addition, competitors may elect to

                                      D-4
<PAGE>

devote substantial resources to marketing their products to similar outlets and
may choose to develop educational and information programs like those developed
by the Company to support their marketing efforts. The Company's business,
financial condition and results of operations could be materially and adversely
affected by any one or more of such developments. Competition for the self-care
products the Company offers is significant. These products compete against a
number of well-known brands of similar products. The Company's failure to
adequately respond to the competitive challenges faced by the products it offers
could have a material adverse effect on its business, financial condition and
results of operations.

            1.12 The Company's Quarterly Financial Results are Likely to
      Fluctuate Significantly and May Fail to Meet or Exceed the Expectations of
      Securities Analysts or Investors, which Could Cause the Price of the
      Company's Stock to Decline Significantly.

      The Company's quarterly operating results may fluctuate significantly
based on factors such as: (i) changes in the acceptance or availability of the
products it offers, (ii) the timing of new product offerings, acquisitions or
other significant events by the Company or its competitors, (iii) regulatory
approvals and legislative changes affecting the products it offers or those of
its competitors, (iv) the timing of expenditures for the expansion of its
operations, and (v) general economic and market conditions and conditions
specific to the health care industry. Due to the Company's short operating
history pursuant to its new business strategy and the difficulty of predicting
demand for the products it offers, the Company is unable to accurately forecast
its revenues. Accordingly, the Company's operating results in one or more future
quarters may fail to meet the expectations of securities analysts or investors,
which could have a material adverse effect on the Company's stock price.

            1.13 The Public Market for the Company's Common Stock may be
      Volatile, and the Price of the Common Stock may Fluctuate for Reasons
      Unrelated to the Company's Operating Performance. A Significant Decline in
      the Price of the Common Stock could Lead to a Class Action Lawsuit Against
      the Company.

      There has been a very limited public market for the Company's common
stock, and the Company does not know whether investor interest in the Company
will lead to the development of a more active trading market. The market prices
and trading volumes for securities of emerging companies, such as the Company,
historically have been highly volatile and have experienced significant
fluctuations both related and unrelated to the operating performance of those
companies. The price of the Company's common stock may fluctuate widely,
depending on many factors, including factors that may cause the Company's
quarterly operating results to fluctuate as well as market expectations and
other factors beyond the Company's control.

                                      D-5
<PAGE>

      2. RISKS RELATED TO THIS FINANCING

            2.1 No rights as stockholders.

      Holders of Convertible Notes will not be entitled to vote, receive
dividends or exercise any of the rights of the Company's stockholders for any
purpose prior to conversion of the Convertible Notes. Thus, actions that
adversely affect the holders of Convertible Notes may be taken without the
approval of such holders.

            2.2 The Convertible Notes are unsecured obligations of the Company.

      The Convertible Notes will be general unsecured obligations, junior in
right of payment to all of the Company's existing and future senior debt. The
Convertible Notes will not be secured by any of the Company's assets, and as
such will be effectively subordinated to any existing and future secured debt of
the Company.

            2.3 Broad Discretion of Use of Proceeds.

      Although the Company's management anticipates utilizing the proceeds of
this financing to provide the Company with working capital and for general
corporate purposes, the Company and its management will retain broad discretion
to allocate the proceeds of this financing as well as the timing of its
expenditures. Lenders will not have the opportunity to evaluate the economic,
financial or other information that the Company and its affiliates may use to
determine how it uses these proceeds. Management's failure to apply these funds
effectively could have a material adverse effect on the Company's business,
financial condition, and results of operations.

            2.4 This is a best efforts Financing.

      The Convertible Notes are being offered on a "best efforts" basis. Thus,
there can be no assurance that all of the offered Convertible Notes will be
sold. Lenders bear the risk that the Company will accept subscriptions for less
than the maximum amount of the financing and then be unable to successfully
complete all of the anticipated uses of the proceeds of the financing. If less
than the maximum amount of the financing is sold, the Company's business,
financial condition and results of operations could be adversely affected.

                                      D-6
<PAGE>

                                   EXHIBIT "E"
<TABLE>

                          Fully Diluted Capitalization
<CAPTION>

------------------------------------------------------------------------------------------------------
                                           Pre-Financing                     Post-Financing
---------------------------------- ----------------------------- -------------------------------------
                                    Number of Shares           %      Number of Shares               %
---------------------------------- ----------------------------- -------------------------------------
<S>                                 <C>                   <C>         <C>                       <C>
Common Stock and
Equivalents (1)                        39,109,680          62.2%         44,009,680(2)           48.5%
---------------------------------- ----------------------------- -------------------------------------
Warrants and Options                   23,807,750          37.8%         23,807,750              26.2%
---------------------------------- ----------------------------- -------------------------------------
Convertible Note Shares (3)                   N/A                         9,000,000              10.0%
---------------------------------- ----------------------------- -------------------------------------
Convertible Note Warrants (4)                 N/A                        13,900,000(5)           15.3%
---------------------------------- ----------------------------- -------------------------------------
TOTAL                                  62,917,430          100%          90,717,430               100%
------------------------------------------------------------------------------------------------------
</TABLE>

--------------------
(1)   Excludes Common Stock issued pursuant to conversion of the Convertible
      Notes and warrants issued in connection therewith.

(2)   Includes the 4,900,000 shares issued in connection with the conversion of
      the UVCA loan as described in Section 6.6.1 above.

(3)   Assumes a $0.05 price per share for the Convertible Notes on an as
      converted basis.

(4)   Assumes a $0.05 exercise price for the warrants on an as converted basis.

(5)   Includes the 4,900,000 warrants issued pursuant to the conversion of the
      UVCA loan as more specifically described in Section 6.6.1 above.

                                       E-1EXHIBIT 10.7

[GRAPHIC OMITTED] Gender Sciences, Inc.
--------------------------------------------------------------------------------
                   10 West Forest Avenue, Englewood, NJ 07631
                  Phone:(201) 569-1188     Fax: (201) 569-3224

                             SUBSCRIPTION AGREEMENT
                             FOR PURCHASE OF SHARES

Dear Gene:

         1.       The undersigned hereby tenders this subscription and applies
for the purchase of the number of shares of common stock (the "Shares") of the
Company, at a purchase price of $.02 per Share, set forth on the signature page
of this Subscription Agreement. The undersigned is hereby subscribing for Shares
and, together with this Subscription Agreement, the undersigned is delivering a
check payable to Gender Sciences, Inc. (the "Company") in the full amount of the
purchase price for the Shares which the undersigned is subscribing for pursuant
hereto or funds by wire transfer as instructed by the Company.

         2.       In order to induce the Company to accept this subscription,
the undersigned hereby represents and warrants to, and covenants with, the
Company as follows:

         (i)      The undersigned has received and reviewed with management
information related to the operations of the Company, including the Company's
Business Plan which includes the five month Cash Burn Analysis, ("CBA"), a copy
of which is attached hereto, a projected timeline for the proposed merger
between the Company and Health Direct, Inc. ("HD") and all public financial
information filed by the Company with the Securities and Exchange Commission. It
is agreed that during the period covered by the "CBA", the Company shall provide
no later than ten (10) days after each monthly period, a statement covering the
preceding monthly sales results. It is further agreed that during the period,
there shall be no increase in salaries to prior levels (before 20% reduction
provided for in the "CBA") or repayment of debt except for the amount shown in
the "CBA" without written approval of the undersigned unless the sales figures
exceed the aggregate projections by thirty percent (30%) for the five months
period, in which case the salaries shall be increased to the salaries prior to
the reduction provided for in the CBA for the next seven months. In the event
that the sales figures do not exceed the projections by thirty percent (30%)
then in such event, the salaries shall remain at the level provided for in the
CBA for the next seven months. At the end of one year, the Board of Directors of
the Company (excluding Arnold and Myra Gans) shall fix the salaries for the next
year. However, such salaries shall not be greater than the salaries in effect
prior to the reduction provided for in the CBA.

         (ii)     The undersigned has had a reasonable opportunity to ask
questions of and receive answers from the Company concerning the Company and all
such questions, if any, have been answered to the full satisfaction of the
undersigned; including conversations between the undersigned and the officers
and principal shareholders of HD;

         (iii)    The undersigned has such knowledge and expertise in financial
and business matters that the undersigned is capable of evaluating the merits
and risks involved in an investment in the Shares;

         (iv)     No representations or warranties have been made to the
undersigned by the Company or any agent, employee or affiliate of the Company
other than as described herein and in entering into this transaction the
undersigned is relying upon such information, and the results of independent
investigation by the undersigned. It is further understood that there is no
assurance that the proposed merger with HD will be consummated or if consummated
within the timeline provided to you or on the terms contemplated herein. It is
understood that if HD shall receive more than 55% of the outstanding shares and
options existing after the consummation of this transaction (in this case, a
total of 59,717,430 shares including the 5,500,000 issued to you and other

--------------------------------------------------------------------------------
     Medical Nutrition, Inc. o Holistic Products Corp. o NutraPet Labs, Inc.
<PAGE>

investors hereunder and an additional 1,250,000 shares to be issued to Gene
Terry or his designee), you will receive additional shares such that your
percentage after the consummation of the HD transaction will be equal to the
percentage of the outstanding stock of the company you would have owned as if HD
had received only 55% of the issued and outstanding stock and options.

         (v)      The undersigned understands that (A) the Shares have not been
registered under the Act or the securities laws of any state, based upon an
exemption from such registration requirements for non-public offerings pursuant
to Regulation D under the Act; (B) the Shares are and will be "restricted
securities", as said term is defined in Rule 144 of the Rules and Regulations
promulgated under the Act; (C) the Shares may not be sold or otherwise
transferred unless they have been first registered under the Act and all
applicable state securities laws, or unless exemptions from such registration
provisions are available with respect to said resale or transfer; (D) except as
otherwise set forth herein, the Company is under no obligation to register the
Shares under the Act or any state securities laws, or to take action to make any
exemption from any such registration provisions available; and (E) the
certificates for the Shares will bear a legend to the effect that the transfer
of the securities represented thereby is subject to the provisions hereof.
Notwithstanding anything herein to the contrary, if the Company shall file a
registration statement covering its shares (including in the case of the
potential merger with HD a proxy statement on FormS-4), it agrees that it will
include those Shares being purchased by the undersigned hereunder in the
registration Statement and the Company shall enter into a customary registration
rights agreement with the undersigned;

         (vi)     The undersigned is acquiring the Shares solely for the account
of the undersigned, for investment purposes only, and not with a view towards
the resale or distribution thereof;

         (vii)    The undersigned will not sell or otherwise transfer any of the
Shares, or any interest therein, unless and until (A) said Shares shall have
first been registered under the Act and all applicable state securities laws; or
(B) the undersigned shall have first delivered to the Company a written opinion
of counsel (which counsel and opinion (in form and substance) shall be
reasonably satisfactory to the Company), to the effect that the proposed sale or
transfer is exempt from the registration provisions of the Act and all
applicable state securities laws;

         (viii)   The undersigned has full power and authority to execute and
deliver this Subscription Agreement and to perform the obligations of the
undersigned thereunder; and such agreement is a legally binding obligation of
the undersigned in accordance with its terms;

         (ix)     The undersigned is an "accredited investor," as such term is
defined in Rule 501 (a) of Regulation D promulgated under the Act;

         (x)      The undersigned has carefully reviewed the jurisdictional
notices listed below and agrees to abide by any restrictions contained therein
applicable to the undersigned.

                             JURISDICTIONAL NOTICES

Residents of All States:

         THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF CERTAIN STATES AND
ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION
REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO
RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 2
<PAGE>

EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR
EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO
BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.
THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY
AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE
MERITS OR THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

                                     * * * *

         3.       The undersigned understands that this subscription is not
binding upon the Company until the Company accepts it, which acceptance is at
the sole discretion of the Company and is to be evidenced by the Company's
execution of this Subscription Agreement where indicated. This Subscription
Agreement shall be null and void if the Company does not accept it as aforesaid.

         4.       The undersigned agrees to indemnify the Company, or any
officer or director of the Company and hold each harmless from and against any
and all losses, damages, liabilities, costs and expenses which it may sustain or
incur in connection with the breach by the undersigned or any representation,
warranty or covenant made by the undersigned.

         5.       Neither this Subscription Agreement nor any of the rights of
the undersigned hereunder may be transferred or assigned by the undersigned
except with respect to transfers or assignments made by the undersigned to
members of the undersigned's family.

         6.       The undersigned acknowledges that the information supplied by
the Company (other than filings pursuant to the Act) is confidential and
non-public and agrees that all such information shall be kept in confidence by
the undersigned and neither used by the undersigned to the undersigned's
personal benefit (other than in connection with this proposed sale) nor
disclosed to any third party for any reason other than in compliance with
applicable law.

         7.       It is understood that in connection with the purchase of the
Shares hereunder so long as the Company continues to pay Arnold Gans his salary
and benefits and conducts its business in accordance with the "CBA", Arnold Gans
agrees that he will not compete with the operations of the Company by becoming
an officer, employee or shareholder, (defined as owning more than 5% of the
issued and outstanding stock), of any company engaged in a business that is
competitive with the operations of the Company. In the event that Arnold Gans
voluntarily terminates his employment with the Company or he is terminated for
"cause" by the Company, then in such case, Arnold Gans agrees not to compete
with the Company for a period of one year from the date of such event. In
addition, Arnold Gans agrees not to disclose, divulge or make available to any
third party any trade secrets or proprietary information about the Company.

         8.       The undersigned is attaching to this Subscription Agreement
true and correct copies of the following documents, as applicable:

                  For Trusts. A trust must attach a copy of its declaration of
trust or other governing instrument, as amended, as well as all other documents
that authorize the trust to invest in the Shares and execute this Subscription
Agreement. Include documents demonstrating authority of the signing individual
to act on behalf of the trust. All documentation must be completed and correct.

                  For Partnerships. A partnership must attach copies of its
partnership agreement, as amended, as well as all other documents that authorize
the partnership to invest in the Shares and execute this Subscription Agreement.
Include documents demonstrating authority of the signing individual to act on

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 3
<PAGE>

behalf of the partnership. All documentation must be completed and correct. If
the partner of the partnership purchasing the Shares which is executing the
Subscription Agreement on behalf of the Partnership is a trust, corporation or
another partnership, the Partnership must supply a copy of such entity's trust
agreement, articles of incorporation and by-laws or partnership agreement, as
applicable.

                  For Corporations. A corporation must attach copies of its
articles of incorporation and by-laws, as amended, in effect as well as all
other documents that authorize the corporation to invest in the Shares and
execute this Subscription Agreement, e.g., resolutions of the board of
directors. Include documents demonstrating authority of the signing individual
to act on behalf of the corporation. All documentation must be completed and
correct.

         9.       This Subscription Agreement (i) may only be modified by a
written instrument executed by the undersigned and the Company; (ii) sets forth
the entire agreement of the undersigned and the Company with respect to the
subject matter hereof; (iii) shall be governed by the laws of the State of New
Jersey applicable to contracts made and to be wholly performed therein; and (iv)
shall inure to the benefit of, and be binding upon the Company and the
undersigned and its respective heirs, legal representatives, successors and
permitted assigns.

         10.      Unless the context otherwise requires, all personal pronouns
used in this Subscription Agreement, whether in the masculine, feminine or
neuter gender, shall include all other genders.

         11.      All notices or other communications hereunder shall be in
writing and shall be deemed to have been duly given if delivered personally or
mailed by certified or registered mail, return receipt requested, postage
prepaid, as follows: if to the undersigned, to the address set forth in this
Agreement; and if to the Company, to Gender Sciences, Inc. 10 West Forest
Avenue, Englewood, New Jersey 07631, or to such other address as the Company or
the undersigned shall have designated to the other by like notice.

         12.      In the event that the Company proposes to issue or sell any
(i) shares of common stock of the Company for a price of less than $.02 per
share, including shares of common stock issued in the proposed merger with HD,
(ii) warrants, options or other rights to purchase shares of common stock of the
Company at a price of less than $.02 per share or (iii) any notes, debentures or
other securities convertible into or exchangeable for shares of common stock of
the Company at a price of less than $.02 per share (collectively "Company
Securities"), the undersigned shall receive a number of such securities so that,
after giving effect to such issuance (and the conversion, exercise and exchange
into or for (whether directly or indirectly) shares of common stock of the
Company of all such company Securities including without limitation any shares
that may be issued as a dividend, interest or similar payment), the undersigned
will continue to maintain its same proportionate equity ownership in the Company
on a fully diluted basis as of the date immediately prior to such issuance. In
the event the Company shall issue any securities having greater rights then the
rights of the investors hereunder from time to time, including voting rights,
liquidation preference, dividends or other similar rights, then in such case the
investors hereunder shall receive such rights.

         13.      It is agreed that in addition to the transactions contemplated
hereby, the Company represents that Gene Terry (or his designee) will purchase
$25,000 of common stock under the same terms and conditions.

         14.      Neither Arnold Gans nor Larry Burstein shall, in any one
transaction or any series of similar transactions, directly or indirectly, sell
any shares of common stock of the Company held by him unless the terms and
conditions of such sale or other disposition to any third-party shall include an
offer by such third-party to the undersigned to include, at the option of the
undersigned, in the sale or disposition to such third-party a pro rata number of
shares of common stock of the Company beneficially owned by the undersigned.

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 4
<PAGE>

         15.      As of the date hereof, prior to the sales contemplated herein,
the Capitalization of the Company consists of 29, 359, 680 shares of common
stock issued and outstanding and 23,607,750 options to purchase shares of common
stock. It is agreed that the Company will not grant any additional options to
Arnold Gans, Myra Gans, Gene Terry or Larry Burstein or any of their affiliates
without the prior approval of the undersigned. Further it is agreed that no
outstanding options will be repriced or extended without the prior approval of
the undersigned. A copy of the original option schedule is annexed hereto as
Exhibit A.

         IN WITNESS WHEREOF, the undersigned has executed this Subscription
Agreement this twelth day of April 2002.

                                 SIGNATURE PAGE
                                 --------------

Organization Signature:                     Individual Signature(s):

                                            /s/ EUGENE TERRY
--------------------------------------      ------------------------------------
Print Name of Subscriber Organization

By:
    ----------------------------------      ------------------------------------
          (Signature and Title)                         Signature(s)

                                            Eugene Terry
--------------------------------------      ------------------------------------
Print Name and Title of Person Signing      Print Name of Subscriber

                                            ------------------------------------
                                            Print Name of Subscriber

**Number of Shares Subscribed for:          1,250,000    @ $0.02
--------------------------------------------------------------------------------

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 5
<PAGE>

                (All Subscribers should please print information
                     below exactly as you wish it to appear
                         in the records of the Company)

Eugene Terry
--------------------------------------      ------------------------------------
Name and capacity in which subscription     Social Security Number of Individual
is Made-see below for particular            or other Tax-payer I.D. Number
requirements

Address:                                    Address for notice if different:

--------------------------------------      ------------------------------------
Number and Street                           Number and Street

--------------------------------------      ------------------------------------
City            State         Zip Code      City            State       Zip Code

Please check the appropriate box to indicate form of ownership (if applicable):

[ ] TENANTS-IN-COMMON                       [ ] JOINT TENANTS WITH
    (Both Parties must sign above)              RIGHT OF SURVIVORSHIP
                                                (Both Parties must sign above)

                           ACCEPTANCE OF SUBSCRIPTION

                              GENDER SCIENCES, INC.

         The foregoing subscription is hereby accepted by Gender Sciences, Inc.
this 12th day of April 2002, for 2,500,000 Shares.

                                            GENDER SCIENCES, INC.

                                            By: /s/ ARNOLD GANS
                                                --------------------------------
                                                Name: Arnold Gans
                                                Title: President

                                            By: /s/ ARNOLD GANS
                                                --------------------------------
                                                Arnold Gans as to paragraph 7 &
                                                14

                                            By: /s/ LAWRENCE BURSTEIN
                                                --------------------------------
                                                Lawrence Burstein as to
                                                paragraph 14

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 6
<PAGE>

                      COMMON STOCK AND OPTION COUNT FOR GSI
                      -------------------------------------

                                 March 21, 2003

TOTAL SHARES ISSUED & OUTSTANDING                                     29,359,680

OPTIONS AVAILABLE FOR EXERCISE                                        23,607,750

TOTAL BEFORE INTERIM FINANCING                                        52,967,430

TOTAL SHARES ISSUED AFTER INTERIM FINANCING                            6,750,000

TOTAL SHARES AFTER INTERIM FINANCING                                  59,717,430

THIS COMMON STOCK AND OPTION COUNT IS BEFORE THE PROPOSED MERGER WITH HEALTH
DIRECT.

                SUBSCRIPTION AGREEMENT FOR PURCHASE OF SHARES - 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]